SCHEMBL7716642

SCHEMBL7716642

CCCC(CC)(CCP(=O)(O)O)C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
GRM4 Q14833 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LPAR3 Q9UBY5 3/20 0.33
FDPS P14324 2/20 0.33
ATM Q13315 2/20 0.33
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LPAR2 Q9HBW0 1/20 0.33
HTT P42858 1/20 0.33
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2048398 0.93 CYP4F2 (0.42) CYP4F2CYP4A11GRM4MEN1KMT2A
SCHEMBL2052355 0.91 CYP4F2 (0.56) CYP4F2CYP4A11GRM4MEN1KMT2A
SCHEMBL29104226 0.86 CYP4F2 (0.60) CYP4F2CYP4A11MEN1KMT2AATM
SCHEMBL2047336 0.83 CYP4F2 (0.47) CYP4F2CYP4A11GRM4MEN1KMT2A
SCHEMBL9152058 0.82 CYP4F2 (0.66) CYP4F2CYP4A11MEN1KMT2AATM
SCHEMBL2687299 0.81 GRM4 (0.37) CYP4F2CYP4A11GRM4LPAR3FDPS
SCHEMBL2239463 0.81 CYP4F2 (0.41) CYP4F2CYP4A11GRM4LPAR3FDPS
SCHEMBL2238644 0.81 CYP4F2 (0.43) CYP4F2CYP4A11MEN1KMT2AFDPS
SCHEMBL2047345 0.81 CYP4F2 (0.49) CYP4F2CYP4A11MEN1KMT2ALPAR3
SCHEMBL2044329 0.81 CYP4F2 (0.49) CYP4F2CYP4A11MEN1KMT2ALPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed